Concord Wealth Partners Bio Line Rx Ltd. Transaction History

Concord Wealth Partners

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$2.65 - $3.35 $530 - $670	-200 Closed	0 $0
Q2 2021 Jul 29, 2021	SELL	$2.63 - $4.88 $2,104 - $3,904	-800 Reduced 80.0%	200 $1,000
Q1 2021 May 13, 2021	BUY	$2.38 - $4.0 $2,380 - $4,000	1,000 New	1,000 $3,000

3.3M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $29.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.